Analogs of NT-3
AssigneeAmgen Inc.
InventorsEllen Ngoi Yin Cheung, Thomas Charles Boone, Susan Irene Hershenson, John David Young
Life of this patent
Estimating the term…
Abstract
The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
Claims18
An isolated DNA molecule encoding a polypeptide analog of neurotrophin factor −3(NT-3), said polypeptide analog having the sequence selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, SEQ ID NO:
- 6 and SEQ ID NO:
- 7 and being characterized by having an isoelectric point which is lower and an in vitro circulating life and/or absorption which is increased relative to the same properties in unmodified NT-3 of native sequence.
A process for the production of a polypeptide analog of a cationic polypeptide selected from the group consisting of SEQ ID NO:
- 3, SEQ ID NO:
- 5, SEQ ID NO:
- 6 and SEQ ID NO:
- 7, wherein the polypeptide analog has an isolectric point which is lower and an in vivo circulating life and/or absorption which is increased relative to those properties in unmodified NT-3 of native sequence, said process comprising culturing under suitable nutrient conditions a prokaryotic or eukaryotic host cell which has been transformed or transfected with an expression vector comprising a DNA molecule encoding said polypeptide analog in a manner allowing the host cell to express the polypeptide, and optionally isolating the polypeptide analog following said expression.
Dependencies are inferred from the claim text.